With respect to Unit IV, formulation manufacturing facility at Pashamylaram, Hyderabad, the inspection is in progress. USFDA audit is an activity under the normal course of business in the pharmaceutical industry, it added.
Earlier on October 7, Aurobindo Pharma
had received Form 483 for the much-awaited Unit VII inspection with seven observations.
The delay in Sandoz deal closure, OAI/WL on the three API facilities and Unit VII Form 483 has meant de-rating in the stock reflected in the correction from Apr-2019 peak. The stock has slipped 45 per cent since its April 2019 peak, while the benchmark S&P BSE Sensex gained 5 per cent during the period.